| Literature DB >> 29279864 |
Yihao Chen1,2, Siyuan Lu1,2, Shasha Zhang3, Yan Li1,2, Zhe Qu1,2, Ying Chen1,2, Bingwei Lu1,2, Xinyan Wang3, Xue Feng1,2.
Abstract
Currently, noninvasive glucose monitoring is not widely appreciated because of its uncertain measurement accuracy, weak blood glucose correlation, and inability to detect hyperglycemia/hypoglycemia during sleep. We present a strategy to design and fabricate a skin-like biosensor system for noninvasive, in situ, and highly accurate intravascular blood glucose monitoring. The system integrates an ultrathin skin-like biosensor with paper battery-powered electrochemical twin channels (ETCs). The designed subcutaneous ETCs drive intravascular blood glucose out of the vessel and transport it to the skin surface. The ultrathin (~3 μm) nanostructured biosensor, with high sensitivity (130.4 μA/mM), fully absorbs and measures the glucose, owing to its extreme conformability. We conducted in vivo human clinical trials. The noninvasive measurement results for intravascular blood glucose showed a high correlation (>0.9) with clinically measured blood glucose levels. The system opens up new prospects for clinical-grade noninvasive continuous glucose monitoring.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29279864 PMCID: PMC5738229 DOI: 10.1126/sciadv.1701629
Source DB: PubMed Journal: Sci Adv ISSN: 2375-2548 Impact factor: 14.136
Fig. 1ETC principle and the skin-like biosensors.
(A) Schematic of the ETCs, which perform HA penetration, glucose refiltration, and glucose outward transportation. (B) Schematic of the ultrathin skin-like biosensor multilayers. (C) Thin, flexible, and biocompatible paper battery attached to the skin surface for ETC measurement. (D) Selective electrochemically deposited dual electrodes of the biosensors (left). The biosensor completely conforms to the skin surface (right).
Fig. 2Electrochemical and mechanical characterization of the device.
(A) Scanning electron microscopy (SEM) micrograph of O-Au (left) and optical micrograph of broken O-PB (right). (B) SEM micrograph of N-Au (left) and optical micrograph of complete N-PB (right). (C) Schematic of surface nanostructure–induced inner flow during ECD (left). Fluid mechanics simulation of the velocity distribution when the inner flow passes over the surface of the nanostructure (right, top) and electrochemical simulation of the growth rate of PB during ECD on N-Au (right, bottom). (D) Deposition current of O-PB (blue) and N-PB (red). (E) CV scan of O-PB (blue) and N-PB (red). (Inset) CV curve of O-PB (−0.05 to 0.35 V versus Ag/AgCl reference electrode at a scan rate of 50 mV/s). (F) Nyquist plot of EIS of O-Au (black), N-Au (red), O-PB (green), and N-PB (blue). (G) Response of N-PB to the same density H2O2 as a function of deposition time (that is, thickness). (H) CV of freshly deposited N-PB and N-PB after 2 months of storage. (I) Young’s modulus and hardness of N-PB (blue) and O-PB (green).
Fig. 3Bionic transfer printing and glucose measurement calibration.
(A) Process of bionic ROSE transfer printing. (B) Serpentine (top) and interdigital (bottom) pattern biosensors transfer-printed by ROSE. (C) CV of a biosensor before and after transfer printing (−0.05 to 0.35 V versus reference electrode at a scan rate of 50 mV/s). Amperometric I-t results of (D) low-density and (E) moderate-density glucose as measured in a calibration experiment. (Inset) Biosensor response as a function of density. (F) The glucose measurement response for 50 to 100 μM at 10 μM per step was repeated four times. (G) Amperometric I-t result of the selective response to glucose (Glu) and other interfering substances: ascorbic acid (AA), HA, uric acid (UA), and lactic acid (LA). (H) Temperature calibration result (TCR) of the temperature sensor.
Fig. 4In vivo clinical trials.
(A) Paper battery being attached to the skin surface for ETC measurement (left), with HA sprayed under the paper battery anode (right). (B) Amperometric I-t result recorded from the biosensor attached to the skin surface. (C) Biosensing response current with (red) and without (blue) the ETC control test. (D) In vivo invasive blood glucose measurement by using a finger-prick glucometer (left) and a venous blood test with vein detained needles (right). (E) Results of hourly glucose monitoring in 1-day period from 10:00 to 23:00 by using a glucometer (red) and ETC devices (blue) (subject 1). (F) Results of 5-day glucose monitoring with the glucometer (red) and ETC devices (blue) (subject 1). (G) Results of blood glucose measured by using a plasma blood test with a vein detained needle (red) and ETC devices (blue) during the OGTT (subjects 2 and 3).